Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel S Key

Showing results (241-250 of 255) with videos related to

Pageof 26
Sort By:
Journal of Thrombosis and Haemostasis : JTH|September 27, 2019
Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia AVincent P Diego, Bernadette W Luu, Marco Hofmann, et al.
Research and Practice in Thrombosis and Haemostasis|December 17, 2024
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trialAndrew D Leavitt, Johnny Mahlangu, Priyanka Raheja, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on HemostasisWolfgang Bergmeier, Silvio Antoniak, Edward M Conway, et al.
Blood|January 27, 2023
Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell diseaseErica M Sparkenbaugh, Michael W Henderson, Megan Miller-Awe, et al.
Hemasphere|March 26, 2025
Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotypeFrancesco Rodeghiero, Lisanna Ghiotto, Luca Pontalto, et al.
Blood Advances|June 14, 2018
A cross-sectional analysis of cardiovascular disease in the hemophilia populationSuman L Sood, Dunlei Cheng, Margaret Ragni, et al.
Blood Advances|March 15, 2021
Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesiclesNadim Tawil, Rayhaan Bassawon, Brian Meehan, et al.
Journal of Thrombosis and Haemostasis : JTH|July 13, 2020
Quantification of citrullinated histones: Development of an improved assay to reliably quantify nucleosomal H3Cit in human plasmaCharlotte Thålin, Katherina Aguilera, Nathan W Hall, et al.
Blood Advances|March 2, 2022
Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19Michael W Henderson, Franciele Lima, Carla Roberta Peachazepi Moraes, et al.
The New England Journal of Medicine|February 22, 2023
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia AJohnny Mahlangu, Radoslaw Kaczmarek, Annette von Drygalski, et al.
Pageof 26

Showing results (241-250 of 255) with videos related to

Sort By:
Pageof 26
Journal of Thrombosis and Haemostasis : JTH|September 27, 2019
Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia AVincent P Diego, Bernadette W Luu, Marco Hofmann, et al.
Research and Practice in Thrombosis and Haemostasis|December 17, 2024
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trialAndrew D Leavitt, Johnny Mahlangu, Priyanka Raheja, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on HemostasisWolfgang Bergmeier, Silvio Antoniak, Edward M Conway, et al.
Blood|January 27, 2023
Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell diseaseErica M Sparkenbaugh, Michael W Henderson, Megan Miller-Awe, et al.
Hemasphere|March 26, 2025
Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotypeFrancesco Rodeghiero, Lisanna Ghiotto, Luca Pontalto, et al.
Blood Advances|June 14, 2018
A cross-sectional analysis of cardiovascular disease in the hemophilia populationSuman L Sood, Dunlei Cheng, Margaret Ragni, et al.
Blood Advances|March 15, 2021
Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesiclesNadim Tawil, Rayhaan Bassawon, Brian Meehan, et al.
Journal of Thrombosis and Haemostasis : JTH|July 13, 2020
Quantification of citrullinated histones: Development of an improved assay to reliably quantify nucleosomal H3Cit in human plasmaCharlotte Thålin, Katherina Aguilera, Nathan W Hall, et al.
Blood Advances|March 2, 2022
Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19Michael W Henderson, Franciele Lima, Carla Roberta Peachazepi Moraes, et al.
The New England Journal of Medicine|February 22, 2023
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia AJohnny Mahlangu, Radoslaw Kaczmarek, Annette von Drygalski, et al.
Pageof 26